Zobrazeno 1 - 10
of 192
pro vyhledávání: '"E. Zerba"'
Autor:
E. Zerba, A. Cork, D. Fernández, P. Santo Orihuela, H. Masuh, F. Camps, A. Fontán, R. A. Alzogaray
Publikováno v:
Molecules, Vol 10, Iss 9, Pp 1190-1196 (2005)
The behavioural responses of the haematophagous bug Triatoma infestans towards some previously identified components of its faeces: 4-methylquinazoline, 2,4- dimethylquinazoline and their mixtures were evaluated using a video tracking system. Fifth i
Externí odkaz:
https://doaj.org/article/211569bfb18242918e8f40ace4d17111
Autor:
Ariella Sasson, Joseph D. Szustakowski, Ryan Golhar, William J. Geese, Stefan Kirov, Han Chang, George Green, Sujaya Srinivasan, Danielle Greenawalt, Kim E. Zerba
Publikováno v:
Molecular Diagnosis & Therapy
Introduction Tumor mutational burden (TMB) has emerged as a clinically relevant biomarker that may be associated with immune checkpoint inhibitor efficacy. Standardization of TMB measurement is essential for implementing diagnostic tools to guide tre
Autor:
Martin Gutierrez, Mark M. Awad, Joseph D. Szustakowski, Suresh S. Ramalingam, Jason Chesney, Justin F. Gainor, Neal Ready, Kim E. Zerba, Pavan S. Reddy, Ian Rabinowitz, Brian Lestini, Mihaela Mates, Xuemei Li, Martin Reck, James Michael Orcutt, George Green, Julie R. Brahmer, David R. Spigel, William J. Geese, Matthew D. Hellmann, Gregory A. Otterson, Kenneth J. O'Byrne, Jacques Jolivet, Wenhua Hu, Luis Paz-Ares, Leora Horn, Han Chang, Hossein Borghaei
Publikováno v:
Journal of Clinical Oncology
PURPOSE CheckMate 568 is an open-label phase II trial that evaluated the efficacy and safety of nivolumab plus low-dose ipilimumab as first-line treatment of advanced/metastatic non–small-cell lung cancer (NSCLC). We assessed the association of eff
Autor:
Virginia Burns, Sucha Sudarsanam, Cory Batenchuk, Vladislav Chizhevsky, Kim E. Zerba, Maher Albitar, Chelsea Jin
Publikováno v:
Journal of Clinical Pathology
AimsAt the time of analysis, two widely used, drug-specific, tumour-cell programmed death ligand 1 (PD-L1) assays were approved by the US Food and Drug Administration for anti-PD-1 therapies: the Dako PD-L1 immunohistochemistry (IHC) 28-8 pharmDx ass
Publikováno v:
Journal of Applied Statistics. 46:272-285
Anti-tumor treatment outcomes in mouse experiments can be challenging to interpret and communicate accurately. In reporting these experiments, rigorous statistical considerations are commonly absent, although statistical applications have been propos
Publikováno v:
Medical and Veterinary Entomology. 31:414-426
The domiciliary presence of Triatoma infestans (Klug) (Hemiptera: Reduviidae) after control interventions was reported in recent years. Toxicological studies showed high levels of resistance to pyrethroids suggesting resistance as one of the main cau
Autor:
Joseph D. Szustakowski, William J. Geese, Ryan Golhar, Kim E. Zerba, Stefan Kirov, Danielle Greenawalt, Sujaya Srinivasan, Han Chang, Ariella Sasson, George Green
IntroductionTumor mutational burden (TMB) has emerged as a clinically relevant biomarker that may be associated with immune checkpoint inhibitor efficacy. Standardization of TMB measurement is essential for implementing diagnostic tools to guide trea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f57199f755bfa45a8e94513c35e4c59b
https://doi.org/10.1101/626143
https://doi.org/10.1101/626143
Autor:
V. Chizhevsky, Gabriel S Krigsfeld, Kim E. Zerba, James William White, James Novotny, J.W. Ragheb
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 104:236-237
Autor:
Neeraj Adya, Marian Navratil, Scott Ely, Zhenhao Qi, Kim E. Zerba, Péter Szabó, Gillian L Dalgliesh, Robin Edwards, James Cooley, James Lu
Publikováno v:
Journal of Clinical Oncology. 37:2593-2593
2593 Background: A multiparameter tumor inflammation assay based on gene expression profiling (TIA-GEP) can extend the utility of IHC to interrogate the tumor microenvironment (TME). Using CD8 expression assessed by IHC (CD8-IHC) as a surrogate for i
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 104:236